Healthcare Industry News: metabolic disease
News Release - December 13, 2006
Kemia Announces Appointment of Senior VP of Business DevelopmentAppointment Adds Significant Experience in Corporate Partnering and Strategic Alliances to the Kemia Management Team
SAN DIEGO--(HSMN NewsFeed)--Kemia announced today that Martin Emanuele, Ph.D., has joined the company as Senior Vice President of Business Development. Dr. Emanuele has more than 19 years of management experience in publicly traded pharmaceutical and biotechnology companies. Prior to joining Kemia, Dr. Emanuele was Vice President, Business Development and Portfolio Management, with Avanir Pharmaceuticals. While at Avanir, Dr. Emanuele completed partnerships with major global pharmaceutical companies that ranked among the largest transactions completed for preclinical stage technologies.
Prior to Avanir, Dr. Emanuele held several senior management positions in research and development and business development with CytRx Corporation and before that with DuPont Critical Care.
Dr. Emanuele earned his Ph.D. in Pharmacology & Experimental Therapeutics from Loyola University of Chicago and an MBA from the University of Colorado.
"Dr. Emanuele brings significant partnering and business development experience to Kemia," said Lewis Shuster, President and CEO of Kemia. "Kemia has several exciting research programs we are looking to partner in 2007. Later in 2007, after we have completed our ongoing Phase IIa clinical trials, we will begin discussing partnering opportunities for our clinical allosteric p38 inhibitor, KC706. Establishing corporate partnerships and strategic alliances will be important in Kemia's development, and we look forward to Marty's future contributions in this area."
Kemia's lead compound, KC706, is a selective, allosteric p38 MAP kinase inhibitor that is currently in Phase IIa clinical trials for the treatment of rheumatoid arthritis and in patients at risk for cardiovascular and metabolic diseases. The p38 protein is an important signaling molecule in inflammation and high levels of p38 activity have been associated with several inflammatory diseases. Additionally, the allosteric binding of KC706 to p38 MAP kinase results in a much longer duration of action and significantly improved safety profile compared to traditional ATP-competitive kinase inhibitors. The extended duration of action also provides the potential for once-daily dosing.
Kemia's earlier stage programs include inhibitors of CCR5 for the treatment of HIV and inflammatory conditions and amylin receptor agonists for the treatment of obesity and diabetes. Kemia's amylin receptor agonists are non-peptide small molecules with the future potential for oral dosing. In animal models, they slow gastric emptying and decrease food intake similarly to the injectable hormone they are designed to mimic. Kemia believes the longer duration of action of a small molecule drug should result in a superior weight loss benefit to patients.
About Kemia, Inc.:
Kemia discovers and develops novel small molecule therapeutics. Kemia focuses on high value disease targets that are validated, but not yet addressed by safe and effective non-injectable drugs. Kemia's competitive advantage includes proprietary chemistries for allosteric inhibition of kinases and for modulation of GPCRs (G-protein coupled receptors), a multi-disciplinary approach to medicinal chemistry, and rigorous ADME and pharmacokinetic evaluation integrated into the lead optimization process. For more information about Kemia please visit www.kemia.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.